1. Khan SS, Coresh J, Pencina MJ, et al. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation. 2023. doi:10.1161/CIR.0000000000001191.
2. Cunillera-Puértolas O, Vizcaya D, Cerain-Herrero MJ, et al. Cardiovascular events and mortality in chronic kidney disease in primary care patients with previous type 2 diabetes and/ or hypertension. A population-based epidemiological study (KIDNEES). BMC Nephrol. 2022;23(1):376. doi:10.1186/s12882-022-02966-6.
3. Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6117. doi:10.15829/1560-4071-2024-6117.
4. Matsushita K, van der Velde M, Astor BC, et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with allcause and cardiovascular mortality in general population cohorts: a collaborative metaanalysis. Lancet. 2010;375(9731):2073-81. doi:10.1016/S0140-6736(10)60674-5.
5. Writing Group for the CKD Prognosis Consortium; Grams ME, Coresh J, Matsushita K, et al. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An IndividualParticipant Data Meta-Analysis. JAMA. 2023;330(13):1266-77. doi:10.1001/jama.2023.17002.
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S): S117-S314. doi:10.1016/j.kint.2023.10.018.
7. Tangri N, Peach EJ, Franzén S, et al. Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL-CKD Study. Adv Ther. 2023;40(6):2869-85. doi:10.1007/s12325-023-02482-5.
8. Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J. 2008;155(5):791-805. doi:10.1016/j.ahj.2008.01.031.
9. Xie X, Liu Y, Perkovic V, et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis. 2016;67(5):728-41. doi:10.1053/j.ajkd.2015.10.011.
10. Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014;(5): CD007784. doi:10.1002/14651858.CD007784.pub2.
11. Tsai WC, Hsu SP, Chiu YL, et al. Cardiovascular and renal efficacy and safety of sodiumglucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2022;12(10): e060655. doi:10.1136/bmjopen-2021-060655.
12. Wheeler DC, Stefánsson BV, Jongs N, et al.; DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22-31. doi:10.1016/S22138587(20)30369-7.
13. Xie Y, Bowe B, Mokdad AH, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94(3):567-81. doi:10.1016/j.kint.2018.04.011.
14. Jonsson AJ, Lund SH, Eriksen BO, et al. The prevalence of chronic kidney disease in Iceland according to KDIGO criteria and age-adapted estimated glomerular filtration rate thresholds. Kidney Int. 2020;98(5):1286-95. doi:10.1016/j.kint.2020.06.017.
15. Lindhardt M, Knudsen ST, Saxild T, et al. Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study. BMC Prim Care. 2025;26(1):23. doi:10.1186/s12875-025-02721-4.
16. Батюшин М. М., Трубникова М. А., Арутюнов Г. П. и др. Анализ данных российского Регистра АУРА (Регистр реальной клинической практики выявляемости АльбУминуРии среди пациентов с ранее недиАгностированной хронической болезнью почек). Российский кардиологический журнал. 2024;29(7):5926. doi:10.15829/1560-4071-2024-5926.
17. Кобалава Ж. Д., Виллевальде С. В., Багманова Н. Х. и др. Распространенность маркеров хронической болезни почек у пациентов с артериальной гипертонией в зависимости от наличия сахарного диабета: результаты эпидемиологического исследования ХРОНОГРАФ. Российский кардиологический журнал. 2018;(2):91-101. doi:10.15829/1560-4071-2018-2-91-101.
18. Ощепкова Е. В., Аксенова А. В., Орловский А. А., Чазова И. Е. Хроническая болезнь почек у амбулаторных больных артериальной гипертонией: клиническая характеристика и эффективность лечения (по данным национального регистра). Терапевтический архив. 2022;94(7):810-5. doi:10.26442/00403660.2022.07.201744.
19. Шамхалова М. Ш., Викулова О. К., Железнякова А. В. и др. Эпидемиология хронической болезни почек у пациентов с диабетом в Российской Федерации по данным Федерального регистра сахарного диабета (2010-2022 гг.). Сахарный диабет. 2023;26(5):404-17. doi:10.14341/DM13090.
20. Межонов Е. М., Рейтблат О. М., Вялкина Ю. А. и др. Хроническая болезнь почек и хроническая сердечная недостаточность: влияние на прогноз и выбор патогенетической терапии. Терапевтический архив. 2024;96(7):66674. doi:10.26442/00403660.2024.07.202781.
21. Shin JI, Chang AR, Grams ME, et al.; CKD Prognosis Consortium. Albuminuria Testing in Hypertension and Diabetes: An Individual-Participant Data Meta-Analysis in a Global Consortium. Hypertension. 2021;78(4):1042-52. doi:10.1161/HYPERTENSIONAHA.121.17323.
22. Comini LO, de Oliveira LC, Borges LD, et al. Prevalence of chronic kidney disease in Brazilians with arterial hypertension and/or diabetes mellitus. J Clin Hypertens (Greenwich). 2020;22(9):1666-73. doi:10.1111/jch.13980.
23. Molokhia M, Okoli GN, Redmond P, et al. Uncoded chronic kidney disease in primary care: a cross-sectional study of inequalities and cardiovascular disease risk management. Br J Gen Pract. 2020;70(700): e785-e792. doi:10.3399/bjgp20X713105.
24. Zhang X, Zhang M, Li C, et al. Association between hypertension duration and chronic kidney disease in residents in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2025;46(1):2632. Chinese. doi:10.3760/cma.j.cn112338-20240411-00187.
25. Hunegnaw A, Mekonnen HS, Techane MA, Agegnehu CD. Prevalence and Associated Factors of Chronic Kidney Disease among Adult Hypertensive Patients at Northwest Amhara Referral Hospitals, Northwest Ethiopia, 2020. Int J Hypertens. 2021;2021:5515832. doi:10.1155/2021/5515832.
26. Yu Y, Wang D, Guo Z, et al. The effect of different levels of systolic blood pressure control on new-onset chronic kidney disease in hypertension multimorbidity. Sci Rep. 2024;14(1):19858. doi:10.1038/s41598-024-71019-9.
27. MacRae C, Mercer SW, Guthrie B, Henderson D. Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care. Br J Gen Pract. 2021;71(704): e243-e249. doi:10.3399/bjgp20X714125.
28. Tanaka T, Maruyama S, Chishima N, et al. Population characteristics and diagnosis rate of chronic kidney disease by eGFR and proteinuria in Japanese clinical practice: an observational database study. Sci Rep. 2024;14(1):5172. doi:10.1038/s41598-024-55827-7.
29. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46. doi:10.1056/NEJMoa2024816.
30. The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):11727. doi:10.1056/NEJMoa2204233.
31. Forbes AK, Hinton W, Feher MD, et al. Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a crosssectional study. EClinicalMedicine. 2024;68:102426. doi:10.1016/j.eclinm.2024.102426.
32. Neuen BL, Jun M, Wick J, et al. Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data. Lancet Reg Health West Pac. 2023;43:100988. doi:10.1016/j.lanwpc.2023.100988.